The study combined analysis of public cancer datasets with clinical tissue samples, laboratory assays and mouse xenografts. Clear cell renal cell carcinoma is the most common histological form of kidney cancer, accounting for approximately 80% of renal cell carcinomas, and the paper reports that both METTL14 and FDX1 are expressed at lower levels in tumors than in matched normal tissue. In The Cancer Genome Atlas cohort, low expression of either gene was associated with shorter overall and disease-free survival. These associations were evaluated in database data rather than through a prospective clinical trial, so they establish a prognostic association but do not show that either protein can be used to predict outcomes reliably in routine practice.

FDX1 encodes a mitochondrial iron-sulfur protein involved in several biochemical processes, including electron transfer, redox catalysis, mitochondrial respiration and protein acylation. It also has a central role in cuproptosis, a copper-dependent form of regulated cell death. In the mechanism described by the investigators, FDX1 reduces divalent copper to monovalent copper, which promotes lipoacylation of proteins such as DLAT and DLST. The study’s authors describe this copper-driven protein modification as a process distinct from apoptosis and ferroptosis, the latter two of which are not inhibited by the cuproptosis pathway in the cited background research. ccRCC cells contained more intracellular divalent copper than the normal renal tubular epithelial cell line used for comparison, suggesting that reduced FDX1 expression was accompanied by impaired handling of copper in the tumor model.

To investigate why FDX1 was diminished in ccRCC, the team examined m6A regulators. m6A is a widespread post-transcriptional modification installed by “writer” proteins and removed by “eraser” proteins. METTL14 is a writer, whereas ZC3H13 is another m6A-associated factor; FTO and ALKBH5 are erasers. Tumor tissue showed reduced expression of METTL14 and ZC3H13 and increased expression of FTO and ALKBH5 in the TCGA analysis. METTL14 had the strongest positive correlation with FDX1 among the four regulators examined, with a reported correlation coefficient of 0.46. Tissue assays, immunostaining and cultured cells likewise showed lower METTL14 in ccRCC samples and cell lines than in their normal counterparts, while low METTL14 expression in the survival dataset was linked to poorer outcomes.

The molecular experiments provided evidence that METTL14 acts directly on the FDX1 transcript. A prediction tool identified potential m6A sites on FDX1 RNA, and RNA immunoprecipitation followed by quantitative PCR showed that m6A enrichment on FDX1 transcripts was lower in the 786-0 and OS-RC-2 ccRCC cell lines than in HK-2 renal tubular epithelial cells. METTL14 binding to FDX1 RNA was similarly reduced in the cancer cell lines. When METTL14 was overexpressed in 786-0 and OS-RC-2 cells, m6A modification of FDX1 mRNA increased, as did FDX1 messenger RNA and protein abundance. Actinomycin D treatment, which was used to block new RNA synthesis, showed that FDX1 RNA degraded more slowly after METTL14 overexpression, indicating that the increase in FDX1 expression was associated with greater transcript stability.

Wild-type METTL14 and a catalytically inactive D314A mutant were then compared in the same cell models. Both constructs were expressed, but only wild-type METTL14 significantly increased FDX1 messenger RNA and protein and slowed FDX1 RNA degradation. The mutant did not produce a comparable change, supporting a requirement for METTL14’s methyltransferase activity rather than a nonspecific effect of METTL14 abundance. This distinction is important because it links the phenotype to the catalytic function of the enzyme. The study did not, however, identify the specific m6A reader protein that binds the modified FDX1 transcript, leaving that part of the pathway unresolved.

Functional assays connected the METTL14-FDX1 relationship to cuproptosis and cellular metabolism. In 786-0 cells, METTL14 overexpression increased the consumption of divalent copper, while simultaneous FDX1 knockdown reduced that effect. In a 72-hour cell-viability experiment using a 300 nM elesclomol-copper complex, METTL14 overexpression was associated with the lowest survival rate, whereas FDX1 knockdown partially reversed the reduction in survival. Oxygen-consumption measurements showed that METTL14 overexpression increased basal and maximal mitochondrial respiration, with the enhancement attenuated by FDX1 depletion. METTL14 also increased lipoacylated DLAT and DLST and intracellular alpha-ketoglutarate; these changes were reversed when FDX1 was knocked down. Together, the assays support a pathway in which METTL14 raises FDX1, FDX1 promotes copper-dependent protein lipoacylation and cuproptosis, and tumor-cell survival falls.

The researchers then tested whether the cellular mechanism translated into an animal model. Groups of five six-week-old male BALB/c nude mice received subcutaneous implants of 786-0 cells carrying an empty vector, stable METTL14 overexpression, or combined METTL14 overexpression and FDX1 knockdown. Tumor volume was measured every four days for 28 days. Tumors derived from METTL14-overexpressing cells grew less and had lower mass than control tumors, while FDX1 knockdown nullified the suppression of growth. Western blotting and immunohistochemical analysis of xenograft tissue showed that METTL14 overexpression increased lipoacylated DLAT and DLST, while FDX1 knockdown abolished that increase. These rescue experiments are important because they show that FDX1 is not merely correlated with tumor behavior in the cell assays but is necessary for the observed effect of METTL14 in vivo.

Overall, the findings support a model in which loss of METTL14 contributes to reduced FDX1 expression in ccRCC by limiting m6A modification and accelerating FDX1 messenger RNA degradation. Reduced FDX1 then corresponds to weaker copper-dependent cell death and greater tumor-cell proliferation, while METTL14 overexpression produces the opposite phenotype in cell cultures and mouse xenografts. The work offers a mechanistic explanation for the previously observed association between low METTL14 or FDX1 expression and poor survival in kidney clear cell carcinoma. It also identifies FDX1-dependent cuproptosis as a measurable functional link between RNA methylation and malignant behavior. The evidence remains preclinical: the clinical sample set included 12 patients with surgically treated ccRCC, the experiments focused on two cancer cell lines and one xenograft model, and the retrospective database associations were not tested as clinical biomarkers. No therapeutic efficacy or safety was demonstrated in patients. The authors note that future work should identify the m6A reader or readers that recognize modified FDX1 RNA, which would complete the molecular description of the pathway.

Subject of Research: METTL14-dependent m6A regulation of FDX1 and cuproptosis in clear cell renal cell carcinoma

Article Title: METTL14-mediated FDX1 m6A methylation inhibited the proliferation of clear cell renal cell carcinoma

Article References: Bai, Z., Wang, C., Shen, J., Yang, Y., Liu, Q., & Shang, Z. (2026). METTL14-mediated FDX1 m6A methylation inhibited the proliferation of clear cell renal cell carcinoma. Medical Oncology, 43(11), Article 341. https://doi.org/10.1007/s12032-026-03438-9

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03438-9

Keywords: clear cell renal cell carcinoma, METTL14, FDX1, m6A methylation, cuproptosis, RNA stability, mitochondrial metabolism, cancer metabolism, xenograft model, METTL14-mediated, methylation, inhibited

The new study, published as an open-access original article in Cellular and Molecular Life Sciences, focuses on a chemical tag known as N6-methyladenosine, or m6A, the most abundant internal modification found in messenger RNA molecules across eukaryotic cells. Far from being decorative, m6A marks act as a dynamic layer of gene regulation: they influence how efficiently a transcript is translated into protein, how long it survives before being degraded, and even where it localizes within the cell. Writers install the mark, readers interpret it, and erasers remove it. The enzyme at the heart of the new findings, alkylation repair homolog protein 5, better known as ALKBH5, belongs to this last category. It is a demethylase, an enzyme that chemically strips m6A marks from RNA, and previous work had implicated it in everything from spermatogenesis to cancer progression. Whether it played any role in the diseased placenta, however, was unknown.

To find out, the researchers began where the disease begins: in placental tissue. Analyzing clinical samples from patients with preeclampsia, they discovered that ALKBH5 was consistently upregulated in the placentas of affected mothers compared with healthy pregnancies. Crucially, this overabundance of the demethylase coincided with a global decrease in m6A levels across placental transcripts, exactly what one would expect if an RNA eraser were working overtime. The same pattern appeared in a mouse model of preeclampsia-like disease, strengthening the case that the observation was not a human-tissue artifact but a reproducible feature of the disorder. The correlation, while compelling, left open the central question of causation: was ALKBH5 merely a bystander in the stressed placenta, or was it actively driving the pathology?

The team turned to a laboratory workhorse to answer that question. HTR8/SVneo cells, an immortalized human trophoblast line widely used to model placental cell behavior, were exposed to hydrogen peroxide to induce oxidative stress, mimicking the hostile environment that trophoblasts face in a preeclamptic placenta. As anticipated, the stressed cells lost their ability to invade and migrate, the very functions that healthy trophoblasts must perform to anchor the placenta and remodel maternal spiral arteries. But when the researchers knocked down ALKBH5 using small interfering RNA, the damage was partially reversed. The treated cells recovered a significant portion of their invasive and migratory capacity, suggesting that ALKBH5 was not simply responding to stress but actively contributing to the functional collapse of trophoblasts under oxidative assault.

With a functional link established, the next challenge was to identify the molecular target through which ALKBH5 exerted its effects. The researchers performed an integrated bioinformatics analysis, cross-referencing the RM2Target database with Gene Expression Omnibus datasets to search for genes that were both regulated by ALKBH5 and relevant to trophoblast biology. The search converged on a single compelling candidate: formyl peptide receptor 2, or FPR2, a G-protein-coupled receptor known to participate in inflammatory signaling. Subsequent validation experiments, including RNA immunoprecipitation and dual-luciferase reporter assays, confirmed that ALKBH5 physically and functionally interacts with FPR2 messenger RNA, establishing FPR2 as a bona fide downstream target of the demethylase.

The mechanistic details that emerged are elegant and, in the context of pregnancy disease, genuinely novel. ALKBH5 binds to the 3′ untranslated region of the FPR2 transcript, the stretch of RNA that follows the protein-coding sequence and typically governs transcript stability. By erasing m6A marks at this location, ALKBH5 stabilizes the FPR2 mRNA, allowing it to persist longer in the cell and driving up the production of the FPR2 receptor protein. In other words, the demethylase does not change the genetic message itself; it changes how long the message survives, and in doing so it amplifies a receptor that ultimately undermines trophoblast behavior. This m6A-dependent stabilization mechanism illustrates how epitranscriptomic regulation, a field barely two decades old, can produce consequences as dramatic as a pregnancy disorder.

The functional experiments sealed the argument. When the researchers overexpressed FPR2 in trophoblasts that had been protected by ALKBH5 knockdown, the protective effect vanished: the cells once again lost their invasive and migratory prowess under oxidative stress. FPR2, it appeared, was the executioner carrying out the damage that ALKBH5 had set in motion. Conversely, when the team administered WRW4, a pharmacological antagonist of FPR2, to mice with preeclampsia-like features, the disease phenotype improved. The antagonist ameliorated the key characteristics of the disorder in the animal model, providing proof of principle that blocking the receptor downstream of ALKBH5 can counteract the pathological process in a living system.

Taken together, the findings define what the authors describe as an ALKBH5–FPR2 axis in preeclampsia pathogenesis: an RNA-erasing enzyme upregulated in the diseased placenta strips methylation marks from FPR2 transcripts, prolongs their half-life, boosts receptor expression, and thereby disrupts the trophoblast functions on which a healthy pregnancy depends. The chain of evidence runs from human placental tissue through cell culture under oxidative stress to a mouse model and back again, with pharmacological rescue at the endpoint. Few studies of preeclampsia have traced a causal pathway with this degree of molecular resolution, and the identification of an epitranscriptomic mechanism in the disorder opens a fresh dimension in a field long dominated by angiogenic factors and immune hypotheses.

The therapeutic implications are tantalizing, though tempered by the usual caveats of early-stage research. Both nodes of the axis offer potential points of intervention: inhibiting ALKBH5 activity or blocking FPR2 signaling with agents such as WRW4 could, in theory, restore trophoblast function before the maternal syndrome takes hold. Because FPR2 already has known pharmacological modulators, the receptor represents a particularly attractive druggable target, and repurposing efforts could accelerate translation. Yet significant hurdles remain. The mouse model recapitulates preeclampsia-like features but not the full human disease, the precise timing and cell types in which the axis operates during human placentation require further mapping, and any intervention in pregnancy demands an exceptionally high safety bar. Still, the study adds a powerful new concept to the preeclampsia literature: that the fate of a pregnancy may hinge not on which genes are present, but on how long their RNA messages endure. As m6A biology continues to reshape our understanding of human disease, the placenta has now joined the list of organs where the epitranscriptome writes, and erases, the story of health.

Subject of Research: The role of the m6A demethylase ALKBH5 and its downstream target FPR2 in the pathogenesis of preeclampsia

Article Title: ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2

Article References: Fan, C., Zhang, C., Liu, L., & Zhang, M. (2026). ALKBH5 contributes to preeclampsia through m6A-dependent upregulation of FPR2. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06471-z

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06471-z

Keywords: preeclampsia, ALKBH5, FPR2, m6A, RNA methylation, epitranscriptomics, trophoblast, placenta, oxidative stress, RNA stability, pregnancy, molecular biology

Long non-coding RNAs, once dismissed as transcriptional noise, are now recognized as powerful regulators of gene expression in cancer. SSTR5-AS1 is an antisense transcript associated with the somatostatin receptor 5 gene locus, and previous work had hinted at its involvement in tumor biology. In the new study, the authors confirmed that SSTR5-AS1 is significantly overexpressed in esophageal cancer samples compared with adjacent healthy tissue, and that high levels of the transcript correlate with poor clinical prognosis. When the researchers measured SSTR5-AS1 in esophageal cancer cell lines, they found the same pattern of enrichment, establishing the RNA as a consistent feature of the malignancy rather than a sporadic artifact of tumor heterogeneity.

To determine what this RNA actually does inside cancer cells, the team performed a series of loss-of-function experiments. When SSTR5-AS1 was knocked down, the cancer cells lost several of their hallmark aggressive behaviors. Proliferation slowed, colony formation in soft agar diminished, and the cells became markedly less capable of migration and invasion, the processes that underpin metastatic spread. These results suggested that SSTR5-AS1 is not a passive bystander in esophageal cancer but an active driver of tumor progression, promoting the phenotypic traits that clinicians fear most.

The most striking discovery, however, concerned how the cells died. Rather than undergoing apoptosis, the conventional form of programmed cell death, SSTR5-AS1-depleted cells displayed the unmistakable biochemical fingerprints of ferroptosis. Levels of lipid reactive oxygen species rose sharply, intracellular ferrous iron accumulated, and malondialdehyde, a canonical marker of lipid peroxidation, increased substantially. At the same time, glutathione, the cell’s principal antioxidant defense, was depleted. When the researchers applied pharmacological inhibitors of ferroptosis, these biochemical changes were reversed and cell survival was restored, confirming that ferroptosis was indeed the mechanism by which SSTR5-AS1 suppression killed the cancer cells.

Ferroptosis has emerged over the past decade as a promising vulnerability in cancer therapy. Because tumor cells often rewire their metabolism to resist apoptosis, inducing ferroptosis offers an alternative route to eliminate them. The new findings place SSTR5-AS1 squarely within this emerging field, identifying it as a brake on ferroptotic death in esophageal cancer. In effect, tumors that overproduce this RNA are better equipped to withstand the oxidative stress that would otherwise destroy their membranes, giving them a decisive survival advantage in the hostile environment of the esophagus.

Having established that SSTR5-AS1 suppresses ferroptosis, the researchers next asked how it exerts this effect at the molecular level. Through RNA-protein interaction analyses, they found that SSTR5-AS1 physically recruits a protein called FAM120A, a factor known to associate with RNA stability complexes. This interaction allows SSTR5-AS1 to stabilize the messenger RNA encoding UHRF1, a well-characterized epigenetic regulator frequently overexpressed in cancers and implicated in maintaining the proliferative state of tumor cells. By protecting UHRF1 mRNA from degradation, the SSTR5-AS1/FAM120A complex keeps UHRF1 protein levels high, which in turn sustains the cellular conditions that prevent ferroptosis from taking hold.

This discovery defines what the authors describe as the SSTR5-AS1/FAM120A/UHRF1 axis, a linear signaling pathway connecting a non-coding RNA to a chromatin-modifying oncogene and ultimately to a specific mode of cell death. The axis provides a coherent mechanistic explanation for the clinical observations: patients whose tumors express high levels of SSTR5-AS1 carry tumors that are simultaneously more invasive and more resistant to ferroptotic elimination. Disrupting any node of this axis, whether by targeting the RNA itself, its protein partner FAM120A, or the downstream UHRF1 message, could theoretically restore the cancer cell’s sensitivity to ferroptosis.

But the story does not end there. The team also investigated what keeps SSTR5-AS1 itself stable and abundant in cancer cells. Their experiments revealed that the RNA is decorated with N6-methyladenosine, or m6A, the most prevalent internal chemical modification found on mammalian messenger and non-coding RNAs. Counterintuitively, rather than marking the transcript for destruction, the m6A marks on SSTR5-AS1 are read by IGF2BP1, an m6A reader protein of the insulin-like growth factor 2 mRNA-binding protein family, which protects the RNA from decay. The methyltransferase METTL3, the principal enzyme that installs m6A marks throughout the transcriptome, was shown to be essential for this process. When METTL3 or IGF2BP1 activity was compromised, SSTR5-AS1 levels fell, and the downstream consequences rippled through the entire axis.

This m6A-dependent stabilization adds a crucial epitranscriptomic layer to the regulatory circuit. It means that the abundance of SSTR5-AS1, and therefore the ferroptosis resistance of esophageal cancer cells, is ultimately controlled by the cell’s RNA modification machinery. The finding aligns with a growing body of evidence that m6A modification acts as a master switch in cancer, influencing everything from stemness and immune evasion to therapy resistance. In this case, the methylation system works in favor of the tumor, ensuring that a pro-survival non-coding RNA remains plentiful precisely where it does the most damage.

The therapeutic implications of the study are considerable. Because SSTR5-AS1 sits upstream of both UHRF1 stabilization and ferroptosis suppression, it represents an attractive target for intervention. Antisense oligonucleotides or small interfering RNAs designed to degrade SSTR5-AS1 could, in principle, strip esophageal cancer cells of their ferroptosis defenses and sensitize them to existing chemoradiotherapy or to emerging ferroptosis-inducing drugs. Alternatively, strategies aimed at blocking the METTL3-IGF2BP1 stabilization of the RNA, or at disrupting the interaction between SSTR5-AS1 and FAM120A, could achieve similar effects at different points in the pathway. The study was supported by the Natural Science Foundation of Hunan Province and approved by the Ethics Committee of the Affiliated Nanhua Hospital, and the authors note that further preclinical validation will be needed before such approaches reach the clinic.

Beyond its immediate relevance to esophageal cancer, the work contributes to a broader conceptual shift in cancer biology. It illustrates how non-coding RNAs, RNA-binding proteins, epigenetic regulators, and RNA chemical modifications can be woven together into a single, coherent circuit that governs a fundamental cell fate decision. Ferroptosis research has largely focused on metabolic enzymes, iron handling, and lipid chemistry; the demonstration that an m6A-modified long non-coding RNA can orchestrate resistance to this death modality expands the field’s mechanistic horizon. As researchers continue to map the epitranscriptomic landscape of tumors, transcripts like SSTR5-AS1 are likely to prove that the most important regulators of cancer survival are not always proteins, and that the dark matter of the genome holds targets worth pursuing.

For patients with esophageal cancer, whose five-year survival rates remain dismally low despite advances in surgery and systemic therapy, the identification of actionable vulnerabilities is urgently needed. The SSTR5-AS1/FAM120A/UHRF1 axis offers a molecularly defined, druggable logic: high SSTR5-AS1 predicts poor outcome, its depletion triggers ferroptotic death, and its stability depends on enzymes and readers that can already be pharmacologically manipulated in laboratory settings. Whether clinical translation follows will depend on the development of safe and effective delivery systems for RNA-targeted therapeutics and on trials that test whether ferroptosis induction can complement existing treatments. For now, the study stands as a compelling example of how basic molecular discovery, pursued at the level of individual RNA transcripts and their chemical marks, can illuminate new paths through one of oncology’s most stubborn challenges.

Subject of Research: m6A-modified long non-coding RNA SSTR5-AS1 regulation of ferroptosis and UHRF1 mRNA stability in esophageal cancer

Article Title: m6A-enriched SSTR5-AS1 regulates ferroptosis through recruiting FAM120A to stabilize UHRF1 mRNA in esophageal cancer

Article References: Zhang, Y., Yan, T., Lin, X., & Wang, M. (2026). m6A-enriched SSTR5-AS1 regulates ferroptosis through recruiting FAM120A to stabilize UHRF1 mRNA in esophageal cancer. Cellular and Molecular Life Sciences. https://doi.org/10.1007/s00018-026-06441-5

Image Credits: AI Generated

DOI: 10.1007/s00018-026-06441-5

Keywords: SSTR5-AS1, esophageal cancer, ferroptosis, m6A modification, METTL3, IGF2BP1, FAM120A, UHRF1, long non-coding RNA, RNA stability, cancer biology, lipid peroxidation